UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

The Lancet (British edition), 2023-08, Vol.402 (10402), p.641-654

2023

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead

The cancer journal (Sudbury, Mass.), 2021-03, Vol.27 (2), p.112-118

2021

Volltextzugriff (PDF)

A clinical perspective on plasma cell leukemia; current status and future directions

Blood cancer journal (New York), 2021-02, Vol.11 (2), p.23-23, Article 23

2021

Volltextzugriff (PDF)

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

The lancet oncology, 2023-07, Vol.24 (7), p.811-822

2023

Volltextzugriff (PDF)

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Blood, 2019-10, Vol.134 (15), p.1247-1256

2019

Volltextzugriff (PDF)

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies

Transfusion (Philadelphia, Pa.), 2019-05, Vol.59 (5), p.1773-1780

2019

Volltextzugriff (PDF)

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

Bone marrow transplantation (Basingstoke), 2021-01, Vol.56 (1), p.202-209

2021

Volltextzugriff (PDF)

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

Blood advances, 2023-12, Vol.7 (23), p.7235-7238

2023

Volltextzugriff (PDF)

Sudden Death by Pulmonary Emboli From Disseminated Mucormycosis in a Transplant Patient on Voriconazole Prophylaxis

Chest, 2014-03, Vol.145 (3), p.621A-1-621A-2

2014

Volltextzugriff (PDF)

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Transplantation and cellular therapy, 2021-01, Vol.27 (1), p.57.e1-57.e8

2021

Volltextzugriff (PDF)

Diagnosis and Management of Multiple Myeloma: A Review

JAMA : the journal of the American Medical Association, 2022-02, Vol.327 (5), p.464

2022

Volltextzugriff (PDF)

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Blood, 2023-11, Vol.142 (Supplement 1), p.3263-3263

2023

Volltextzugriff (PDF)

Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions

Blood, 2023-11, Vol.142 (Supplement 1), p.1976-1976

2023

Volltextzugriff (PDF)

Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters

Biology of blood and marrow transplantation, 2019-09, Vol.25 (9), p.e293-e297

2019

Volltextzugriff (PDF)

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

Blood, 2023-11, Vol.142 (Supplement 1), p.330-330

2023

Volltextzugriff (PDF)

sup.90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

Bone marrow transplantation (Basingstoke), 2021-01, Vol.56 (1), p.202

2021

Volltextzugriff (PDF)

CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S346-S346

2024

Volltextzugriff (PDF)

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S155-S155

2024

Volltextzugriff (PDF)

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S180-S180

2024

Volltextzugriff (PDF)

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.551-551

2021

Volltextzugriff (PDF)

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

Blood, 2018-11, Vol.132 (Supplement 1), p.198-198

2018

Volltextzugriff (PDF)

CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S320-S321

2023

Volltextzugriff (PDF)

POSTER: CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S174-S174

2023

Volltextzugriff (PDF)

Oral Abstract: CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S146-S146

2023

Volltextzugriff (PDF)

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.204-204

2019

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(46)
Buchkapitel
(1)

Sprache

Englisch
(47)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Hematology
(10)
Humans
(9)
Multiple Myeloma
(7)
Transplantation
(6)
Female
(4)
Hematopoietic Stem Cell Transplantation
(4)
Leukemia
(4)
Aged
(3)
Antigens
(3)
Bone Marrow
(3)
Chimeric Antigen Receptors
(3)
Chronic Lymphocytic Leukemia
(3)
General & Internal Medicine
(3)
Hematology, Oncology And Palliative Medicine
(3)
Immunotherapy
(3)
Induction Therapy
(3)
Lymphocytes
(3)
Lymphocytes T
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study

Chimeric Antigen Receptor T Cells for Multiple Myeloma: The Journey So Far-And the Road Ahead

A clinical perspective on plasma cell leukemia; current status and future directions

γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies

90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma

Sudden Death by Pulmonary Emboli From Disseminated Mucormycosis in a Transplant Patient on Voriconazole Prophylaxis

Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma

Diagnosis and Management of Multiple Myeloma: A Review

Undetectable MRD Status in Patients with R/R CLL/SLL with Stable Disease after Lisocabtagene Maraleucel Treatment: Exploratory Analysis of the TRANSCEND CLL 004 Study

Resistance to CD38 Antigen Targeted Therapy in Multiple Myeloma May Result from Underrecognized Chromosome 4 Gene Deletions

Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters

Lisocabtagene Maraleucel (liso-cel) in R/R CLL/SLL: 24-Month Median Follow-up of TRANSCEND CLL 004

sup.90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

CLL-184 Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis

CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

POSTER: CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

Oral Abstract: CLL-094 Lisocabtagene Maraleucel (liso-cel) in R/R Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

Suchergebnisse filtern